between amino acid 11 and 24, as well as in between amino acid 22 and 34. The 7-39 region of Der pII therefore contains two binding sites for IgG of non-atopic individuals.

Page 25, replace the paragraph beginning at line 21 with the following paragraph:

The compound of the invention can be prepared by recombinant cDNA technology to produce a polypeptide made of a series of repetitive units of T and B cell epitope-containing peptides. A polypeptide made of a duplicated T cell epitope derived from TT (amino acids 830 to 844 of the heavy chain) and six repetitive B cell epitopes derived from Der pII is produced by DNA technology. A sequence of two amino acid residues is inserted in between each epitope. The sequence is: D - $(QYIKANSKFIGITELX)_2$ - $(CHGSEPCIIHRGKPFX)_5$ - CHGSEPCIIHRGKPFSR, (SEQ ID NO. 3), in which X is GG or SS.

Page 29, replace the paragraph beginning at line 23 with the following paragraph:

The peptide is used for mouse immunization. Thus, six BALB/c mice are injected in each footpad with 50 µl of an emulsion containing 50 µg of the peptide in complete Freund's adjuvant. The same injection procedure is used twice at a fortnight interval, except for the use of incomplete Freund's adjuvant. Two weeks after the last injection, the mice are bled and the serum shown to contain specific antibodies to the Der pII B cell epitope included in the synthetic peptide used for immunization, and to full-length Der pII protein. Regional draining lymph nodes are obtained for the preparation of T cell suspension. The latter are shown to proliferate in the presence of TT, but not in the presence of Der pII or the peptide corresponding to the B cell moiety used for immunization.

Page 30, replace the paragraph beginning at line 16 with the following paragraph:

A core peptide made of 8 lysine (K) residues is made synthetically. Each K epsilon-